Suboxone Lawsuit (2026): Tooth Decay Claims & MDL Status

Suboxone is a sublingual film containing buprenorphine and naloxone used to treat opioid use disorder, and lawsuits allege the film caused severe tooth decay and dental erosion. These cases are centralized in a federal multidistrict litigation, and as of June 2026 the litigation remains active. This page explains the claims, the regulatory record, and the current status neutrally.

This page is part of our Mass Tort & Product Liability overview.

What Suboxone is and the alleged harm

Suboxone is a brand-name medicine that combines buprenorphine and naloxone in a thin film placed under the tongue or against the inside of the cheek, where it dissolves. It is a widely used treatment for opioid use disorder and is also part of a class of buprenorphine products used for pain. The lawsuits allege that the sublingual film is acidic and that, because it dissolves in direct contact with the teeth and gums, it can contribute to serious dental problems, including tooth decay, enamel erosion, cavities, oral infections, and tooth loss. Plaintiffs generally claim the manufacturer designed an acidic film and knew, or should have known, of the dental risk yet failed to provide an adequate warning until required to do so. These claims are typically brought as failure-to-warn and design-defect product liability cases. This describes the allegations, not a finding that Suboxone caused any individual's dental injury.

Note: These are allegations being tested in court. A lawsuit reflects what a plaintiff claims, not a final determination of liability, and outcomes can differ from case to case.

What the science and regulators say

The regulatory record centers on the U.S. Food and Drug Administration. On January 12, 2022, the FDA issued a Drug Safety Communication warning that dental problems, including tooth decay, cavities, oral infections, and loss of teeth, have been reported with buprenorphine medicines that are dissolved in the mouth, and that these problems have occurred even in patients with no history of dental issues. The FDA said it had identified 305 such cases in its adverse-event reporting, including reports involving multiple teeth, and required a new warning about the risk to be added to the prescribing information and the patient Medication Guide for all buprenorphine medicines dissolved in the mouth. Importantly, the FDA also stated that buprenorphine remains an important treatment for opioid use disorder and pain and that the benefits of these medicines clearly outweigh the risks, advising patients not to stop taking them without talking to a health-care professional. Some published research has reported higher rates of dental disease among patients using sublingual buprenorphine compared with other forms.

Note: The FDA warning identifies an association and required a label change; it is not a finding that the product caused any specific person's tooth loss. Patients should not stop a prescribed medicine based on this page and should consult their prescriber.

The status of the Suboxone litigation (as of October 2026)

Most federal Suboxone dental cases are consolidated in In re: Suboxone (Buprenorphine/Naloxone) Film Products Liability Litigation, MDL No. 3092, in the U.S. District Court for the Northern District of Ohio before Judge J. Philip Calabrese, under master docket 1:24-md-3092. The Judicial Panel on Multidistrict Litigation created the MDL in 2024 to coordinate cases sharing common questions about whether the film's acidity causes dental erosion and decay and whether the defendants failed to warn. According to court records, roughly 1,800 cases were pending in the MDL as of mid-2026, and the court has issued case-management orders and addressed pretrial motions, including a ruling on a motion to dismiss.

The court now has a detailed bellwether protocol in place. Under Second Amended Case Management Order No. 15, entered March 27, 2026, a pool of 500 randomly identified plaintiffs narrows to a 50-case Core Discovery Pool, then to a 15-case Trial Pool the parties are to select by January 29, 2027, and finally to four cases for trial, with the court deciding which of those four is tried first. The order's proposed schedule contemplates a first trial setting in March 2028, but the court stated it will reduce that schedule to an order later, so it is a working timetable rather than a fixed trial date.

As of October 2026 there is no general settlement resolving the Suboxone dental claims, and no bellwether verdicts have established a value for these cases. Litigation status changes over time, so the current posture should be confirmed before relying on any description of it.

Who may be involved

The people generally involved in this litigation are individuals who used Suboxone sublingual film, or another buprenorphine medicine dissolved in the mouth, and later developed significant dental problems such as severe tooth decay, erosion, cavities requiring extensive treatment, or tooth loss. Whether any particular person may have a claim depends on the specific facts, including which product was used and for how long, the nature and timing of the dental injury, dental and prescription records, and the law of the relevant state. Use of the medicine and a later dental problem, on their own, do not establish a claim, and many people who take buprenorphine do not develop serious dental injury. Nothing here suggests that every user has a claim or that any outcome is assured.

Deadlines and why they matter

Claims like these are subject to statutes of limitations, which are legal deadlines to file suit. These deadlines vary by state and by the type of claim, and many states measure the deadline from when a person knew or reasonably should have known that an injury may be linked to the product, a concept sometimes called the discovery rule. Because the deadline depends on your state and your facts, there is no single national filing deadline, and this page does not state any individual's deadline. Missing a deadline can permanently bar a claim, so people who believe they may be affected often act promptly rather than waiting. A licensed attorney in the relevant state can evaluate which deadline applies to a specific situation.

How to evaluate your options

If you are trying to understand your legal options, the appropriate step is to speak with a licensed attorney who handles this type of case. An attorney can assess the facts, explain the applicable law in your state, and advise whether you may have a claim; this page cannot do that. It can help to gather any records you have, such as proof of which buprenorphine product you used and when, your prescription history, and dental records documenting the injury and its timing. Most mass tort and personal injury attorneys offer a free, confidential consultation, and many work on a contingency basis, meaning a fee is generally owed only if there is a recovery. A consultation creates no obligation to file, and you should not stop taking a prescribed medication without first consulting your health-care provider.

Frequently Asked Questions

What is the Suboxone lawsuit about?

It involves claims that Suboxone sublingual film, which contains buprenorphine and naloxone and dissolves in the mouth, caused severe dental problems such as tooth decay, erosion, and tooth loss, and that the manufacturer failed to adequately warn of the risk. The cases are typically brought as failure-to-warn and design-defect product liability claims under state law.

Is there a Suboxone MDL, and what is the case number?

Yes. Most federal Suboxone dental cases are consolidated in In re: Suboxone (Buprenorphine/Naloxone) Film Products Liability Litigation, MDL No. 3092, in the U.S. District Court for the Northern District of Ohio before Judge J. Philip Calabrese (master docket 1:24-md-3092).

What did the FDA say about Suboxone and teeth?

In a Drug Safety Communication dated January 12, 2022, the FDA warned that dental problems, including tooth decay, cavities, oral infections, and tooth loss, have been reported with buprenorphine medicines dissolved in the mouth, and it required a new warning to be added to the prescribing information and Medication Guide. The FDA also said the medicines remain important and that their benefits clearly outweigh the risks.

Is there a settlement?

As of June 2026 there is no general settlement resolving the Suboxone dental claims, and no bellwether verdicts have set a value for these cases. The MDL is in pretrial stages. Litigation status can change, so confirm the current posture before relying on any figure.

Who qualifies to file a claim?

There is no automatic qualification. Whether a person may have a claim depends on the specific facts, including which buprenorphine product was used and for how long, the nature and timing of the dental injury, and the law of the relevant state. A licensed attorney can evaluate eligibility.

How much are Suboxone cases worth?

There is no guaranteed amount. The litigation is in pretrial stages, no settlement or bellwether trials have set values, and any recovery would depend on the individual facts. No outcome is promised.

Is there a deadline to file?

Yes, but it varies. Statutes of limitations differ by state and by the type of claim, and many states measure the deadline from when a person reasonably should have connected an injury to the product. There is no single national deadline, so the applicable one should be confirmed with an attorney in the relevant state.

Do I have to pay upfront?

Most mass tort and personal injury attorneys offer a free, confidential consultation and work on a contingency basis, meaning a fee is generally owed only if there is a recovery. Confirm the specific terms with any attorney you consult.